Related references
Note: Only part of the references are listed.Cellular and Molecular Mechanisms of Metformin Action
Traci E. LaMoia et al.
ENDOCRINE REVIEWS (2021)
Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
Andrea Giaccari et al.
DIABETES CARE (2021)
Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study
Jia-Li Feng et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study
Carlos A. Alvarez et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2021)
The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective
Loranne Agius et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Insulin receptor endocytosis in the pathophysiology of insulin resistance
Catherine Hall et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Insulin: too much of a good thing is bad
Hubert Kolb et al.
BMC MEDICINE (2020)
Pathophysiology of Type 2 Diabetes Mellitus
Unai Galicia-Garcia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Prostaglandylinositol cyclic phosphate, the natural antagonist of cyclicAMP
Heinrich K. Wasner
IUBMB LIFE (2020)
Increased Plasma Levels of Adenylate Cyclase 8 and cAMP Are Associated with Obesity and Type 2 Diabetes: Results from a Cross-Sectional Study
Samy M. Abdel-Halim et al.
BIOLOGY-BASEL (2020)
Adenylyl cyclase 5-generated cAMP controls cerebral vascular reactivity during diabetic hyperglycemia
Arsalan U. Syed et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Metformin as Anti-Aging Therapy: Is It for Everyone?
Alexander A. Soukas et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2019)
Metformin Use and Metformin-associated Lactic Acidosis in Intensive Care Unit Patients with Diabetes
Venkat Rajasurya et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2019)
Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo
Anila K. Madiraju et al.
NATURE MEDICINE (2018)
Risk of lactic acidosis in type 2 diabetes patients using metformin: A case control study
Abdellatif Aharaz et al.
PLOS ONE (2018)
Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses
Vanesa Bellou et al.
PLOS ONE (2018)
Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function A Community-Based Cohort Study
Benjamin Lazarus et al.
JAMA INTERNAL MEDICINE (2018)
The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review
Sarah Louise Fishman et al.
MOLECULAR MEDICINE (2018)
The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy
Fatima Ardito et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
Covalent inhibition of protein tyrosine phosphatases
Kasi Viswanatharaju Ruddraraju et al.
MOLECULAR BIOSYSTEMS (2017)
Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries
Bettina Hartmann et al.
PLOS ONE (2017)
A new perspective on metformin therapy in type 1 diabetes
Rachel Livingstone et al.
DIABETOLOGIA (2017)
The mechanisms of action of metformin
Graham Rena et al.
DIABETOLOGIA (2017)
Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling
Zi-yu Zhou et al.
ACTA PHARMACOLOGICA SINICA (2016)
Metformin-associated lactic acidosis: Current perspectives on causes and risk
Ralph DeFronzo et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Lactic Acidosis in a Patient with Type 2 Diabetes Mellitus
Lawrence S. Weisberg
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Metabolically normal obese people are protected from adverse effects following weight gain
Elisa Fabbrini et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Protein Ser/Thr phosphatases - the ugly ducklings of cell signalling
David L. Brautigan
FEBS JOURNAL (2013)
Direct comparison of inositol phosphoglycan with prostaglandylinositol cyclic phosphate, two potential mediators of insulin action
HK Wasner et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2003)
Prostaglandylinositol cyclic phosphate (cPIP): a novel second messenger of insulin action. Comparative analysis of two kinds of 'insulin mediators'
PN Shashkin et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2001)
Phosphatidylinositol 3-kinase and prostaglandylinositol cyclic phosphate (cyclic PIP), a mediator of insulin action, in the signal transduction of insulin
A Gypakis et al.
BIOLOGICAL CHEMISTRY (2000)
Two different mechanisms for activation of cyclic PIP synthase: by a G protein or by protein tyrosine phosphorylation
HK Wasner et al.
BIOLOGICAL CHEMISTRY (2000)
Share Paper
